Zovaglutide

Human clinical Weight Loss & Metabolism 3 sources

Zovaglutide (ZT002) is a novel, ultra-long-acting GLP-1 receptor agonist designed for once-monthly subcutaneous administration. Research indicates it produces clinically meaningful weight loss and cardiometabolic improvements in individuals with overweight or obesity, with a safety profile comparable to existing GLP-1 therapies.

01Dosing reference

Amount

80-160 mg

Frequency

Once monthly (or every two weeks during dose escalation)

Cycle

Continuous use for chronic weight management

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

GLP-1 Receptor Activation

Zovaglutide selectively binds to and activates the glucagon-like peptide-1 (GLP-1) receptor, with no activity at GIP or glucagon receptors.

Extended Half-Life via Albumin Binding

An innovative dual fatty acid chain modification significantly enhances its binding affinity to albumin in the blood, prolonging systemic exposure and allowing for once-monthly dosing.

Metabolic and Appetite Regulation

It exerts metabolic effects through central and peripheral GLP-1 pathways, promoting satiety, reducing caloric intake, and enhancing glucose-dependent insulin secretion.

03Human evidence

In a Phase 2 trial, patients receiving 160 mg of zovaglutide once monthly experienced a 13.8% reduction in body weight at 24 weeks.

A randomized, double-blind, placebo-controlled study involving 303 overweight or obese subjects. The efficacy was highly comparable to reductions observed in patients receiving 80 mg every other week (12.5%).

Zovaglutide demonstrated a favorable safety and tolerability profile, with gastrointestinal adverse events similar to marketed GLP-1 RA products.

Phase 2 trial data showed that most adverse events were mild or moderate, primarily occurring during the dose escalation period, and decreased once the target dose was reached.

04Preclinical evidence

A dual fatty acid-conjugated GLP-1 receptor agonist (TE-8105, related mechanism) showed enhanced diabetes, obesity, and NASH efficacy compared to semaglutide.

Preclinical studies in mice demonstrated improved long-term glycemic control, weight loss, and reduction of liver steatosis.

Zovaglutide enhances albumin-binding capacity via dual fatty acid chain modification, prolonging systemic exposure time.

In vitro studies confirming the mechanism of action for its extended half-life.

05What is known vs. unknown

Reasonably established

Zovaglutide is an ultra-long-acting GLP-1 receptor agonist designed for once-monthly dosing.
It utilizes a dual fatty acid chain modification to enhance albumin binding and extend its half-life.
Phase 2 clinical trials show significant weight loss (up to 13.8% at 24 weeks) in overweight or obese individuals.
It improves cardiometabolic risk indicators, including waist circumference, blood pressure, and lipid profiles.

Unknowns & limits

Long-term cardiovascular outcomes and durability of weight loss beyond 24-30 weeks are not yet fully established.
Phase 3 clinical trials are currently ongoing to confirm efficacy and safety in larger populations.

06Safety & regulatory context

Regulatory statusZovaglutide is currently an investigational drug in Phase 3 clinical trials and is not yet FDA-approved. In Phase 1 and 2 trials, it was generally well-tolerated, with a safety profile consistent with other GLP-1 receptor agonists. The most common adverse events were gastrointestinal, such as nausea, vomiting, and diarrhea, which typically occurred during the dose escalation phase and were mostly mild to moderate in severity. Contraindications are expected to be similar to other GLP-1 RAs, including a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

07Compared with Semaglutide

Zovaglutide vs. Semaglutide

Key difference

Zovaglutide is designed for once-monthly administration due to its dual fatty acid chain modification, whereas semaglutide is typically administered once weekly.

When researchers discuss each

Researchers discuss semaglutide as the current standard of care for weekly GLP-1 therapy in obesity and diabetes, while zovaglutide is discussed as a next-generation option aiming to improve patient compliance through less frequent (monthly) dosing.

08Glossary

GLP-1 Receptor Agonist

A class of medications that mimic the action of the naturally occurring hormone GLP-1, which helps regulate blood sugar levels and appetite.

Dual Fatty Acid Chain Modification

A structural change made to a peptide molecule where two fatty acid chains are attached, significantly increasing its ability to bind to proteins like albumin in the blood, thereby extending how long the drug stays active in the body.

Albumin Binding

The process by which a drug attaches to albumin, the most abundant protein in blood plasma, which helps transport the drug and prevents it from being rapidly cleared by the kidneys.

09Knowledge check

Q1What structural modification allows Zovaglutide to be administered once monthly?

Q2In Phase 2 clinical trials, what was the approximate percentage of body weight reduction observed in patients receiving 160 mg of Zovaglutide once monthly at 24 weeks?

Q3Which documented limitation of the zovaglutide evidence is explicitly noted in the dossier?

Q4How do researchers in the dossier primarily frame zovaglutide when compared with semaglutide?

Q5Which statement about zovaglutide’s regulatory or safety context is supported by the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.